

Office of Research  
Institutional Review Board

MEMORANDUM

---

To: Brigitte E. Miller, M.D.  
OB\_GYN - GYN Oncology

From: Director  
Institutional Review Board

Date: January 19, 2005

Subject: Human Protocol: BG04-267  
A Phase II Study of Single Agent Depsipeptide (FK228) in Recurrent Platinum Sensitive  
Adeno-Carcinoma of the Ovary or Peritoneum CCCWFU 83403 – Amendment #4

The Institutional Review Board voted approval of the amendments listed below at its meeting of January 19, 2005. This action of the full Board does not extend the term of approval for this protocol.

The amendment includes the following:

- Eligibility Criteria: Deletion of "Day 1 before and after...as outlined in Appendix L" and addition of "Day 1 EKG within...administration of depsipeptide."
- Administrative, editorial and clarifying changes.

This IRB is in compliance with the requirements of Part 56, 21 Code of Federal Regulations published as of April 1994 and Part 46, Subpart A of 45 CFR published January 26, 1981.



Wesley Byerly, Pharm.D.

cc: Megan Whelen